Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Publication of UY30159A1publicationCriticalpatent/UY30159A1/en
La presente invención consiste en un método para el tratamiento de la adicción y/o del abuso de sustancias que comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de uno o más nuevos derivados de benzo-heteroaril sulfamida de la fórmula (I) según se definieron en la presentelThe present invention consists of a method for the treatment of addiction and / or substance abuse that comprises administering to a subject in need thereof a therapeutically effective amount of one or more new benzo-heteroaryl sulfamide derivatives of the formula (I) as defined in the present
UY30159A2006-02-152007-02-14
USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR THE TREATMENT OF ADDICTION AND SUBSTANCE ABUSE
UY30159A1
(en)
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
"method for treating hyperproliferative dysfunction, pharmaceutical composition, use of a therapeutic combination in the manufacture of a medicament for treating cancer, article of manufacture for treating a hyperproliferative dysfunction, method for determining compounds to be used in combination for the treatment of cancer". cancer treatment and method for determining a therapeutic combination to be used for cancer treatment "
Phenylalanine derivative compounds; preparation process; pharmaceutical composition comprising said compound; and use of the compound as integrin inhibitors for the treatment of cancer.
CRYSTAL FORM A OF THE COMPOUND 4- [3- (4-CYCLOPROPANCARBONIL-PIPERAZIN-1-CARBONIL) -4-FLUORO-BENCIL] -2H-FTALAZIN-1-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF A
Insulin conjugated compound; preparation procedure; pharmaceutical composition comprising it; pharmaceutical combination; pharmaceutical kit; use in the treatment of insulin-mediated disorders.
Compounds derived from spirooxoindole, antagonist of the interaction between p53 and mdm2; pharmaceutical composition comprising it; to a pharmaceutical kit; use in the treatment of cancer.
Compounds derived from quinoline or benzopyran hiv replication inhibitors; pharmaceutical composition comprising said compounds; and its use in the treatment of a hiv infection
A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
Use of a composition comprising an h1 antagonist, and an anti-tnf alpha compound to treat allergic conjunctivitis or allergic rhinitis in a human subject
Compounds derived from piperidine-carboxamide, renin inhibitors; pharmaceutical composition that includes them; and use in the treatment or prevention of a circulatory disease, hypertension and / or various organic damages attributable to hypertension.
Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.